Resuscitation Institute at Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.
Crit Care Clin. 2012 Apr;28(2):245-70. doi: 10.1016/j.ccc.2012.02.001.
Successful resuscitation from cardiac arrest requires reestablishment of aerobic metabolism by reperfusion with oxygenated blood of tissues that have been deprived of oxygen for variables periods of time. However, reperfusion concomitantly activates pathogenic mechanisms known as “reperfusion injury.” At the core of reperfusion injury are mitochondria, playing a critical role as effectors and targets of such injury. Mitochondrial injury compromises oxidative phosphorylation and also prompts release of cytochrome to the cytosol and bloodstream where it correlates with severity of injury. Main drivers of such injury include Ca overload and oxidative stress. Preclinical work shows that limiting myocardial cytosolic Na overload at the time of reperfusion attenuates mitochondrial Ca overload and maintains oxidative phosphorylation yielding functional myocardial benefits that include preservation of left ventricular distensibility. Preservation of left ventricular distensibility enables hemodynamically more effective chest compression. Similar myocardial effect have been reported using erythropoietin hypothesized to protect mitochondrial bioenergetic function presumably through activation of pathways similar to those activated during preconditioning. Incorporation of novel and clinical relevant strategies to protect mitochondrial bioenergetic function are expected to attenuate injury at the time of reperfusion and enhance organ viability ultimately improving resuscitation and survival from cardiac arrest.
心脏骤停的复苏需要通过含氧血液再灌注来重新建立有氧代谢,使组织重新获得氧气,这些组织已经缺氧了不同的时间。然而,再灌注同时激活了被称为“再灌注损伤”的致病机制。再灌注损伤的核心是线粒体,作为这种损伤的效应器和靶点发挥着关键作用。线粒体损伤会损害氧化磷酸化,还会促使细胞色素释放到细胞质和血液中,其含量与损伤的严重程度相关。这种损伤的主要驱动因素包括钙超载和氧化应激。临床前研究表明,在再灌注时限制心肌细胞溶质 Na 超载,可以减轻线粒体钙超载,维持氧化磷酸化,从而产生有益的心肌功能,包括左心室舒张功能的维持。左心室舒张功能的维持可以使胸外按压更有效地改善血液动力学。据报道,使用促红细胞生成素也可以产生类似的心肌效应,据推测,它可以通过激活类似于预处理过程中激活的途径来保护线粒体生物能功能。采用新的和临床相关的策略来保护线粒体生物能功能有望减轻再灌注时的损伤,提高器官活力,最终改善心脏骤停的复苏和生存。